While initial clinical studies in prostate cancer suggested that a number of HR mutations predict sensitivity to PARP inhibitors, subsequent studies showed that the benefit was primarily seen in patients with BRCA mutations (5). The gene discussed is PARP1; the disease is prostate cancer.